Hong Kong, June 30 -- COVAXIN, India's first 'indigenous' vaccine developed by the Hyderabad-based biotechnology firm Bharat Biotech, has received a green light for Phase I and II human clinical trials. The trials will start in July across the country.

Amid the torrential rise in coronavirus cases that have hit the 1 crore plus mark globally, India (the fourth worst-hit country) is glaring at over 5 lakh confirmed cases, which is close to the total number of deaths around the world. Despite months of lockdown and now easing the lockdown due to economic crisis, India is yet to reach its peak numbers. On the brink of Unlock 2.0, India just received an update on its first, homegrown COVID-19 vaccine.

COVAXIN is an inactivated vaccine, crea...